Simplex Trading
FDMT icon

Simplex Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Simplex Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$931 Buy
+100
New +$870 ﹤0.01% 8615
2025
Q4 		– Sell
-17,900
Closed -$155K – 8994
2025
Q3 		$155K Buy
17,900
+17,500
+4,375% +$105K ﹤0.01% 5233
2025
Q2 		$1K Sell
400
-900
-69% -$3.16K ﹤0.01% 8311
2025
Q1 		$4K Sell
1,300
-10,500
-89% -$49.5K ﹤0.01% 7662
2024
Q4 		$65K Buy
11,800
+5,800
+97% +$45.5K ﹤0.01% 5591
2024
Q3 		$64K Buy
6,000
+4,900
+445% +$81.3K ﹤0.01% 5661
2024
Q2 		$23K Sell
1,100
-7,900
-88% -$198K ﹤0.01% 6763
2024
Q1 		$286K Buy
9,000
+3,300
+58% +$84.2K ﹤0.01% 4457
2023
Q4 		$115K Buy
5,700
+5,600
+5,600% +$73.7K ﹤0.01% 5237
2023
Q3 		$1K Sell
100
-7,100
-99% -$119K ﹤0.01% 8299
2023
Q2 		$130K Sell
7,200
-3,500
-33% -$64.4K ﹤0.01% 4770
2023
Q1 		$183K Buy
10,700
+9,300
+664% +$181K ﹤0.01% 4434
2022
Q4 		$31K Sell
1,400
-3,700
-73% -$57.1K ﹤0.01% 6418
2022
Q3 		$41K Sell
5,100
-1,100
-18% -$9.96K ﹤0.01% 6699
2022
Q2 		$43K Buy
6,200
+900
+17% +$8.75K ﹤0.01% 6693
2022
Q1 		$80K Buy
+5,300
New +$83.2K ﹤0.01% 6465

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Simplex Trading's FDMT Position: Q1 2026 in Review

Simplex Trading opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 21,660 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #4285 among its holdings. This is a return to the name: Simplex Trading previously reported a position in FDMT as recently as Q3 2025.

Simplex Trading first reported a position in FDMT in Q2 2022 and has held it in 9 quarters since. The position peaked at $225K in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Simplex Trading held 21,660 shares of 4D Molecular Therapeutics worth $202K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Simplex Trading position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4285 holding.
  • Simplex Trading first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • Simplex Trading's 4D Molecular Therapeutics position peaked at $225K in Q4 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.